Black Hawk Acquisition Corp (BKHA): Total Liabilities
$3.90M
As of 2025-11-30
$4.75M
As of 2026-08-31
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-11-30 | $3.90M | +56.8% | 2026-03-06, Balance as of period end |
| 2024-11-30 | $2.49M | +867.9% | 2026-03-06, Balance as of period end |
| 2023-11-30 | $256.9K | n/a | 2025-02-07, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Black Hawk Acquisition Corp (BKHA) | 2025-11-30 | $3.90M | +56.8% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $22.92M | -19.8% |
| CEL SCI Corp (CVM) | 2025-09-30 | $12.20M | -13.6% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $58.74M | -71.5% |
| Curis Inc (CRIS) | 2025-12-31 | $14.50M | -69.3% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $50.77M | -50.2% |
| IN8BIO, Inc. (INAB) | 2025-12-31 | $4.72M | -26.9% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $8.83M | +18.2% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $2.89M | +120.8% |
Compare BKHA, CSBR, CVM, ATRA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗